|Podcasts|April 26, 2018

A Challenging Case: Carbon Monoxide Poisoning and Parkinsonian Symptoms

A unique case of chronic, low level carbon monoxide poisoning in a car mechanic that resulted in Parkinsonian symptoms.

It is well known that severe carbon monoxide poisoning can result in Parkinsonian symptoms.

This case report by Eric Hirsch, a medical student at SUNY Downstate, describes a unique case of chronic, low level carbon monoxide poisoning in a car mechanic that resulted in Parkinsonian symptoms and MRI evidence of bilateral necrosis in the globus pallidus.

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Related to this article

September 22nd, 2026

From Biomarkers to Prevention: Key Alzheimer Research Stories of 2026

In recognition of World Alzheimer's Day, NeurologyLive reviews Alzheimer disease developments from 2026, spanning blood-based biomarkers, emerging treatments, prevention research, disease risk factors, and safety considerations surrounding anti-amyloid therapies.

September 22nd, 2026

CHMP Recommends EU Approval for Ocrelizumab in Pediatric Relapsing MS

The positive opinion for intravenous ocrelizumab was supported by phase 3 OPERETTA 2 findings demonstrating noninferior relapse control and superior suppression of MRI-detected brain lesions compared with fingolimod in pediatric patients with relapsing MS.

September 22nd, 2026

Simufilam Clears FDA Hold, Advances to Phase 2 Trial of Tuberous Sclerosis Complex

The FDA lifted a clinical hold on simufilam, clearing Filana Therapeutics, formerly Cassava Sciences, to begin a phase 2a study in TSC-related epilepsy.

September 22nd, 2026

Ulefnersen Meets Primary End Point in Phase 3 FUSION Trial for FUS-ALS

Ulefnersen met its primary end point in the phase 3 FUSION trial, providing the first placebo-controlled evidence for a genetically targeted therapy in FUS-ALS.

September 22nd, 2026

Group-Based Resilience Program Improves Psychological Outcomes in Multiple Sclerosis

An ACT–based group intervention did not significantly improve resilience at 3 months in patients with MS but was associated with improvements in anxiety, well-being, psychological flexibility, and health-related quality of life.

September 22nd, 2026

Qihuang Needle Acupuncture Improves Motor and Nonmotor Parkinson Disease Symptoms

A recently published study showed that Qihuang needle acupuncture significantly improved motor function, nonmotor symptoms, and quality of life in patients with PD when added to standard medication.

September 21st, 2026

Xenon Submits New Drug Application for Azetukalner as Treatment for Focal Seizures

Xenon Pharmaceuticals submitted an FDA new drug application for azetukalner, a KV7 potassium channel opener, as adjunctive therapy for focal seizures in epilepsy.

September 21st, 2026

Gefurulimab Recommended for EU Approval in Generalized Myasthenia Gravis

The CHMP recommended approval of gefurulimab (Klygefa), a weekly, self-administered C5 inhibitor, for AChR-antibody-positive generalized myasthenia gravis in the EU.

A Challenging Case: Carbon Monoxide Poisoning and Parkinsonian Symptoms

Related to this article

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Ulefnersen Meets Primary End Point in Phase 3 FUSION Trial for FUS-ALS

Xenon Submits New Drug Application for Azetukalner as Treatment for Focal Seizures

Gefurulimab Recommended for EU Approval in Generalized Myasthenia Gravis

Group-Based Resilience Program Improves Psychological Outcomes in Multiple Sclerosis

FDA Approves Levacetylleucine for Ataxia-Telangiectasia